Navigation Links
Alzheimer's prevention trial to monitor reactions to higher disease risk status
Date:3/19/2014

PHILADELPHIA - A new clinical trial will soon begin testing whether early medical intervention in people at risk for Alzheimer's can slow down progression of disease pathology before symptoms emerge, as outlined in Science Translational Medicine. For the first time, people with no Alzheimer's disease symptoms will be told of their risk status before being asked to join the randomized controlled trial. As part of the overall prevention trial, Penn Medicine neurodegenerative ethics experts will monitor how learning about their risk of developing Alzheimer's impacts trial participants.

Alzheimer's disease afflicts more than 13 percent of individuals over the age of 65, and remains one of the most feared consequences of aging.

"In order to ethically conduct a study where patients will learn they have a greater chance of developing Alzheimer's disease dementia, we've integrated continual assessments of potential participants throughout the process, to ensure that they are ready to receive information about their amyloid status and aren't having any adverse reactions after finding out," said Jason Karlawish, MD, professor of Medicine and Medical Ethics and Health Policy in the Perelman School of Medicine at the University of Pennsylvania and Associate Director of the Penn Memory Center.

Dr. Karlawish directs the Penn Neurodegenerative Disease Ethics and Policy Program. "This study is an important step in determining the consequences of being tested for Alzheimer's disease before the person has disabling cognitive impairments."

The A4 trial requires that patients enrolled must have one of the pathologies typically seen in Alzheimer's disease dementia, which will be assessed using a brain PET scan that measures amyloid. Given that studies have shown that about one third of clinically normal older individuals have evidence of amyloid plaque accumulation but may not develop any cognitive symptoms within their lifetime, the patients who are enrolled in the trial based on positive amyloid results may or may not go on to develop Alzheimer's disease dementia.

"In addition to the study's primary aims - looking at whether early treatment can slow cognitive decline - we will carefully measure how disclosure impacts cognitive test performance, the perception of cognitive symptoms, quality of life and perceived risk of Alzheimer's in participants with and without evidence of amyloid accumulation," said Karlawish.


'/>"/>

Contact: Kim Menard
kim.menard@uphs.upenn.edu
215-662-6183
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Indoor Memory Maker Triathlon Raises Funds for Alzheimers
2. Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency And CIDP Potentially Supplemented by Approval for Alzheimers Disease Available at ResearchMoz.us
3. Columbia study finds hospitals dont follow infection prevention rules
4. Aspirin still overprescribed for stroke prevention in AF
5. Athletes “Toward Injury Prevention in Sports” TIPS Gets Going in Las Vegas
6. Why Are Young Breast Cancer Patients More Likely to Die from Their Disease? Researchers at the Cancer Prevention Institute of California Find Answers
7. HealthyHispanicLiving Contributor Dr. Jeffrey Weitzel Discusses How Understanding the Cultural Values of Latinas Helps Raise Awareness of Breast Cancer Risk & Prevention
8. Pregnancy Stretch Marks Prevention Cream by Revitol Now Offers Extra Discount as New Year Special
9. Knellinger Dental Excellence Brings Laser Gum Disease Treatment for Bone Stimulation and Possible Tooth Loss Prevention
10. NYSATA Athletic Trainers Provide Injury Prevention and Management on Movie Set
11. “Sleepiness Prevention Tips,” A New Article On Vkool.com, Teaches People How to Fight Sleepiness Naturally - V-kool
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 2016 , ... As part of its ongoing series of aquatic therapy related ... features a dynamic expert and thoughtful presentation to give attendees a better sense of ... events are free to attend, but registration is required. , Rehabilitation of ...
(Date:2/10/2016)... Tenn. (PRWEB) , ... February 10, 2016 , ... ... the American Academy of Emergency Medicine , an emergency medicine professional ... practice management services . , The American Academy of Emergency Medicine, or ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... of a master charity program created to assist the local community. Pledging to ... community leaders and nonprofit organizations in the area. Their goal is to bring ...
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water ... were three leading bottled water brand owners that topped the list as a result ... and optimize conversion. The premier brand was Tibet 5100, a top notch water company ...
(Date:2/10/2016)... ... 10, 2016 , ... Dr. Jessica Barron, of Barron Family Dental in ... patients and families in the North Metro Denver area. The new dental practice focuses ... dentistry, and all in the most relaxing environment. , While some dental visits can ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016  Visage Imaging ... Medicus Ltd. (ASX: PME), has announced that the American ... Florida (UF) have selected the Visage 7 Enterprise ... of the Emergent/Critical Care Imaging SIMulation (SIM). SIM ... Diagnostic Imaging Program (WIDI), a multi-faceted and fully-integrated ...
(Date:2/10/2016)... , February 10, 2016 CERS ), ... ADMS ) and Celldex Therapeutics, Inc. (NASDAQ: CLDX ... MDVN ), Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS ) and ... Today,s latest Orphan Drug Designations become vitally important in the ... to novel drugs and biologics which are defined as those ...
(Date:2/10/2016)... Israel , February 10, 2016 /PRNewswire/ ... leader in the field of cartilage repair, announces the ... 5, 2016. The $15 million investment was led by ... pharmaceutical manufacturer, and was joined by existing Regentis investors ... and both the Technion Research & Development Foundation and ...
Breaking Medicine Technology: